Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Overview of platelet glycoprotein IIb IIIa receptor antagonist treatment in the management of coronary interventions and acute ischemic coronary syndromes
Autore:
Bessmertny, O; Cheng, JWM;
Indirizzi:
Mt Sinai Med Ctr, New York, NY 10029 USA Mt Sinai Med Ctr New York NY USA10029 ai Med Ctr, New York, NY 10029 USA LongUSAl Univ, Arnold & Marie Schwartz Coll Pharm & Hlth Sci, New York, NYLong Isl Univ New York NY USA hwartz Coll Pharm & Hlth Sci, New York, NY
Titolo Testata:
AMERICAN JOURNAL OF MANAGED CARE
fascicolo: 5, volume: 5, anno: 1999,
pagine: 643 - 655
SICI:
1088-0224(199905)5:5<643:OOPGII>2.0.ZU;2-K
Fonte:
ISI
Lingua:
ENG
Soggetto:
ACUTE MYOCARDIAL-INFARCTION; IIB/IIIA INTEGRIN RECEPTOR; COST-EFFECTIVENESS; HEART-DISEASE; PLASMINOGEN-ACTIVATOR; UNSTABLE ANGINA; TRIAL; PHARMACOLOGY; INHIBITORS; ABCIXIMAB;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Social & Behavioral Sciences
Clinical Medicine
Citazioni:
48
Recensione:
Indirizzi per estratti:
Indirizzo: Cheng, JWM Mt Sinai Med Ctr, 1 Gustave L Levy Pl,Box 1211, New York, NY 10029 USA Mt Sinai Med Ctr 1 Gustave L Levy Pl,Box 1211 New York NY USA 10029
Citazione:
O. Bessmertny e J.W.M. Cheng, "Overview of platelet glycoprotein IIb IIIa receptor antagonist treatment in the management of coronary interventions and acute ischemic coronary syndromes", AM J M CARE, 5(5), 1999, pp. 643-655

Abstract

This exercise is intended for primary care physicians, cardiologists, and those individuals concerned with formulary decisions. GOALTo provide a review of the pathogenesis of acute ischemic coronary syndrome, as well as an understanding of the role of glycoprotein IIb/IIIa inhibitors in the management of acute ischemic coronary syndrome. OBJECTIVES1. Describe the role of platelets in the pathogenesis of acute ischemic coronary syndrome.2. Compare the clinical pharmacology, pharmacokinetics, and therapeutic indications of the 3 glycoprotein IIb/IIIa inhibitors currently available on the U.S. market (abciximab, eptifibatide, and tirofiban).3. Discuss published clinical trials on glycoprotein IIb/IIIa inhibitors in the management of acute ischemic coronary syndromes.4. Describe the cost and cost effectiveness of using glycoprotein IIb/IIIain the management of acute ischemic coronary syndromes.5. Provide the reader with the information to make optimal, institution-specific formulary decisions about glycoprotein IIb/IIIa inhibitors based on their clinical pharmacology, efficacy in different patient populations, side effects, and cost-effectiveness.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 27/10/20 alle ore 10:45:57